Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Postoperative Pain
Interventions: Oxytocin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lumbar Spine Degeneration
Interventions: saline 0.9%, Liposomal bupivacaine; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: BPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, Intubation
Interventions: Caffeine Citrate, Placebo (Normal Saline); Drug
Lead sponsor: Jennifer Shepherd; Other
Eligibility: Up to 1 Day
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Pregnancy
Interventions: Hydromorphone, Hyperbaric bupivacaine, Fentanyl; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Shoulder Osteoarthritis, Cuff Tear Arthropathy, Massive Rotator Cuff Tear
Interventions: Local infiltration analgesia, Interscalene block; Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Thyroid Eye Disease
Interventions: Teprotumumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more

Conditions: Diabetes
Interventions: Exendin (9-39), acyl ghrelin, saline; Drug
Lead sponsor: David Dalessio; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Heart Defects, Congenital, Cardiopulmonary Bypass
Interventions: nesiritide, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 1 Year
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Heart Failure
Interventions: mRNA-0184, Placebo; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 1 more

Conditions: Osteoarthritis
Interventions: Monovisc®, Saline; Device · Other
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 30
States / cities: Hoover, Alabama • Mesa, Arizona • Phoenix, Arizona + 27 more

Conditions: BK Virus (Nephropathy)
Interventions: Cidofovir, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions: 80 mg RPH-104, Placebo; Biological · Drug
Lead sponsor: R-Pharm Overseas, Inc.; Industry
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Certolizumab pegol; Other · Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Diabetic Chronic Kidney Disease
Interventions: GCS-100, Placebo; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Chula Vista, California • El Centro, California • La Jolla, California + 5 more

Conditions: Anthrax
Interventions: BioThrax, AV7909, Sodium chloride injection USP, 0.9% (placebo); Biological · Drug
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more

Conditions: Carcinoid Syndrome
Interventions: Lanreotide, Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 16
States / cities: Los Angeles, California • Stanford, California • West Hollywood, California + 11 more

Conditions: Heart Transplant
Interventions: tocilizumab, Placebo, Standard of Care Triple IS; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 20
States / cities: Beverly Hills, California • La Jolla, California • Stanford, California + 15 more

Conditions: Surgical Site Infection
Interventions: IrriSept System, No Intervention - Standard of Care (SoC) only; Device · Other
Lead sponsor: Irrimax Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more

Conditions: Alzheimer Disease
Interventions: 18F-Fluselenamyl; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Septic Shock
Interventions: hydrocortisone, Normal Saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
Interventions: IGIV-C, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 3
States / cities: Wichita, Kansas • Syracuse, New York • San Antonio, Texas

Conditions: Chronic Rhinosinusitis (Diagnosis)
Interventions: Isotonic saline, Hypertonic Nasal Wash, Fluticasone Propionate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cocaine Use Disorder
Interventions: Semaglutide, Placebo, cognitive behavioral therapy (CBT).; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

A Randomized Trial of Exparel vs Saline in Opioid Reduction of Pain Management Following Lumbar Spine Surgeries.

Early Caffeine in Preterm Neonates

Intrathecal Hydromorphone for Labor Analgesia

Local Infiltration Analgesia Vs. Interscalene Block in Total Shoulder Arthorplasty

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Ghrelin Effect on Beta Cell Function in Health and Disease

Nesiritide Use Following Cardiac Surgery in Infants

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

Safety and Effectiveness of Monovisc® Injection for Osteoarthritis of the Knee

Cidofovir in Renal Transplant Recipients With BKVN

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

BARDA Securing Anthrax Immunity For the Elderly

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Tocilizumab in Cardiac Transplantation

Irrisept Versus Standard of Care in the Prevention of Surgical Site Infections

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder